Flupirtine as Oral Treatment in Multiple Sclerosis
Status:
Terminated
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
Flupirtine, a non-opioid analgesic drug, that has been shown to have additional
neuroprotective functions, is given twice daily as an oral medication in patients with
relapsing remitting multiple sclerosis over a period of 12 months. Neuroprotection is
assessed by magnetic resonance imaging, magnetic resonance spectroscopy, optical coherence
tomography, and clinical examination.